United Therapeutics (UTHR) Total Debt (2009 - 2025)

United Therapeutics has disclosed Total Debt across 17 years of filings, most recently posting $200.0 million for Q1 2025.

• In Q1 2025, Total Debt fell 66.67% year-over-year to $200.0 million; the TTM figure through Mar 2025 stood at $200.0 million (down 66.67% YoY), while the FY2024 annual figure was $300.0 million, down 57.14% from the prior year.
• Total Debt came in at $200.0 million for Q1 2025 at United Therapeutics, down from $300.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $800.0 million in Q1 2021 to a low of $200.0 million in Q1 2025.
• Average Total Debt over 5 years is $676.5 million, with a median of $800.0 million recorded in 2021.
• Year-over-year, Total Debt changed 0.0% in 2021 and plunged 66.67% in 2025.
• Over 5 years, Total Debt stood at $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then declined by 12.5% to $700.0 million in 2023, then tumbled by 57.14% to $300.0 million in 2024, then slumped by 33.33% to $200.0 million in 2025.
• Per Business Quant data, the three most recent Total Debt figures were $200.0 million in Q1 2025, $300.0 million in Q4 2024, and $400.0 million in Q3 2024.